TABLE I. Demographic aspects, HIV laboratory parameters and combination antiretroviral therapy (cART) of the patients enrolled in this study.
| Case | Age | Sex | Race | CD4 | Log | cART /time of usea |
| 1 | 48 | F | NW | 441 | - | AZT, 3TC, EFZ/2 years |
| 2 | 33 | F | NW | 6 | 5.453 | AZT, 3TC, EFZ/4 months |
| 3 | 52 | F | NW | 1,846 | 2.476 | TDFb ,3TC, EFV/8 years |
| 4 | 30 | M | W | 282 | - | AZT, 3TC, EFZ/1 year |
| 5 | 32 | M | NW | 19 | 5.032 | No |
| 6 | 51 | M | W | 571 | - | AZT+3TC+EFV/15 years |
| 7 | 28 | F | NW | 41 | 5.610 | No |
| 8 | 33 | M | NW | 329 | 4.681 | No |
| 9 | 29 | M | NW | 369 | 3.544 | No |
| 10 | 46 | M | W | 84 | 4.546 | No |
| 11 | 24 | F | NW | 432 | 4.439 | No |
| 12 | 43 | M | NW | 9 | 5.084 | 3TC+EFV+ddI+LPV/r/2 months |
| 13 | 41 | F | NW | 195 | - | No |
| 14 | 32 | M | NW | 98 | 4.631 | No |
| 15 | 28 | M | W | 242 | 3.361 | 3TC+TDF+EFV/<1 month |
ART: antiretroviral; AZT: zidovudine; ddI: didanosine; EFV: efavirenz; F: female; Log: viral load values in a logarithmic scale; LPV/r: lopinavir/ritonavir; M: male; NW: non-white; TDF: tenofovir; W: white; 3TC: lamivudine; a: time between the onset of cART and anti-tuberculosis treatment; b: use of stavudine for 5 years before TDF.